Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 17/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451407 | 0.88 | ADORA1 (0.55) | ADORA1ADORA2ARPS6KA3 | |
| SCHEMBL5447978 | 0.82 | ADORA1 (0.69) | ADORA1ADORA2AADORA2BDHFR | |
| SCHEMBL5459579 | 0.81 | ADORA1 (0.55) | ADORA1ADORA2AADORA2BDHFR | |
| SCHEMBL1554437 | 0.80 | ADORA1 (0.57) | ADORA1ADORA2ARPS6KA3ADORA2BDHFR | |
| SCHEMBL5460965 | 0.80 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BDHFR | |
| SCHEMBL5453709 | 0.80 | ADORA1 (0.48) | ADORA1ADORA2ARPS6KA3ADORA2BDHFR | |
| Ammonia Solution, Strong SCHEMBL5454694 | 0.79 | ADORA1 (0.52) | ADORA1ADORA2AADORA2BDHFR | |
| SCHEMBL5455439 | 0.79 | ADORA1 (0.45) | ADORA1ADORA2ARPS6KA3ADORA2B | |
| SCHEMBL2326188 | 0.78 | ADORA2A (1.00) | ADORA1ADORA2AADORA2B | |
| SCHEMBL1553929 | 0.77 | ADORA1 (0.61) | ADORA1ADORA2ARPS6KA3ADORA2BDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189717-B2 | Medicinal compositions promoting bowel movement | EISAI CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2007-03-08 | — | — | US | disclosed |
| US-20060270674-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2006-11-30 | — | — | US | disclosed |
| EP-1510222-A2 | Medicinal compositions promoting bowel movement | Eisai Co. Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1283056-B1 | MEDICINAL COMPOSITIONS PROMOTING BOWEL MOVEMENT | EISAI CO LTD (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1283056-A1 | MEDICINAL COMPOSITIONS PROMOTING BOWEL MOVEMENT | Eisai Co., Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885RPS6KA3 2817/4885 |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885RPS6KA3 2263/4885 |
| US-20060270674-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885RPS6KA3 3032/4885 |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | ADORA2A, ADORA3, ADORA2B | ADORA1 4/4885ADORA2A 1/4885RPS6KA3 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.